Complexities of MRD Assays in ALL: A Guide for the Practicing Clinician

Assessment of measurable residual disease (MRD) is an important component of acute lymphoblastic leukemia (ALL) management. Quantification of MRD may be performed through a variety of assays, each with differing sensitivity for leukemia detection. In this review article, we focus on complexities that the treating physician may face when considering MRD in ALL. New information on the optimal MRD assay for Philadelphia chromosome positive ALL, specimen source for MRD testing (eg, blood, bone marrow, cerebrospinal fluid), when to test, and updates on MRD in T-cell ALL are included.